18. Sept. 2018
...."A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ABUS.
DekaBank Deutsche Girozentrale acquired a new position in Arbutus Biopharma in the 1st quarter valued at about $174,000.
Rhumbline Advisers acquired a new position in Arbutus Biopharma in the 2nd quarter valued at about $243,000.
Algert Global LLC acquired a new position in Arbutus Biopharma in the 2nd quarter valued at about $254,000.
Citadel Advisors LLC grew its position in Arbutus Biopharma by 124.9% in the 1st quarter. Citadel Advisors LLC now owns 64,797 shares of the biopharmaceutical company’s stock valued at $324,000 after acquiring an additional 35,981 shares in the last quarter.
Finally,
Millennium Management LLC grew its position in Arbutus Biopharma by 309.1% in the 4th quarter. Millennium Management LLC now owns 82,007 shares of the biopharmaceutical company’s stock valued at $414,000 after acquiring an additional 61,961 shares in the last quarter.
40.05% of the stock is owned by institutional investors...."
zolmax.com/investing/...terly-sales-of-230000-00/2552563.html
...."A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ABUS.
DekaBank Deutsche Girozentrale acquired a new position in Arbutus Biopharma in the 1st quarter valued at about $174,000.
Rhumbline Advisers acquired a new position in Arbutus Biopharma in the 2nd quarter valued at about $243,000.
Algert Global LLC acquired a new position in Arbutus Biopharma in the 2nd quarter valued at about $254,000.
Citadel Advisors LLC grew its position in Arbutus Biopharma by 124.9% in the 1st quarter. Citadel Advisors LLC now owns 64,797 shares of the biopharmaceutical company’s stock valued at $324,000 after acquiring an additional 35,981 shares in the last quarter.
Finally,
Millennium Management LLC grew its position in Arbutus Biopharma by 309.1% in the 4th quarter. Millennium Management LLC now owns 82,007 shares of the biopharmaceutical company’s stock valued at $414,000 after acquiring an additional 61,961 shares in the last quarter.
40.05% of the stock is owned by institutional investors...."
zolmax.com/investing/...terly-sales-of-230000-00/2552563.html